Role of endothelin receptor A and NADPH oxidase in vascular abnormalities

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 787-794

  Dai, De Zai ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Diabetes; ETA; Hypercholesterolemia; Peripheral artery disease; Vascular dilatation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; AMLODIPINE; BERBERINE; BERBERINE DERIVATIVE; BIOLOGICAL MARKER; CANDESARTAN; CHELERYTHRINE; CHLORTALIDONE; CPU 0213; CPU 86017; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIURETIC AGENT; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR ANTAGONIST; ISORHAMNETIN; NITRIC OXIDE; PARA BENZYL TETRA HYDRO BERBERINE; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REHMANNIA EXTRACT; SPIRONOLACTONE; TELMISARTAN; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; VALSARTAN; ENDOTHELIN A RECEPTOR;

ADD ON THERAPY; AGING; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE ACTIVITY; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RECEPTOR UPREGULATION; REVIEW; RISK REDUCTION; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION; ANIMAL; BLOOD VESSEL; HYPERLIPIDEMIA; METABOLISM; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANKLE BRACHIAL INDEX; BLOOD VESSELS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; NADPH OXIDASE; NITRIC OXIDE; OBESITY; OXIDATIVE STRESS; PERIPHERAL ARTERIAL DISEASE; RECEPTOR, ENDOTHELIN A; SIGNAL TRANSDUCTION;

EID: 79952052384     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S6556     Document Type: Review

References (70)

1. Su W, Dai DZ, Liu HR, Na T, Dai Y. Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni. Clin Exp Pharmacol Physiol. 2007;34(12):1228-1233.
2. Dobarro D, Gómez-Rubín MC, Sanchez-Recalde A, et al. Current pharmacological approach to restore endothelial dysfunction. Cardiovasc Hematol Agents Med Chem. 2009;7(3):212-222.
3. Shah R. Endothelins in health and disease. Eur J Intern Med. 2007;18(4): 272-282.
4. Romero M, Jiménez R, Sánchez M, et al. Quercetin inhibits vascular superoxide production induced by endothelin-1: role of NADPH oxidase, uncoupled eNOS and PKC. Atherosclerosis. 2009;202(1):58-67.
5. Liu HR, Tang XY, Dai DZ, Dai Y. Ethanol extracts of Rehmannia complex (Di Huang) containing no Corni fructus improve early diabetic nephropathy by combining suppression on the ET-ROS axis with modulate hypoglycemic effect in rats. J Ethnopharmacol. 2008;118(3): 466-472.
6. Dai DZ. The antiarrhythmic activity of protoberberines in relation to blockade of ion channels. Ion Channel Modulators ID Research Alert. 1997;2:383-390.
7. Dai DZ. CPU86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels. Cardiovasc Drug Rev. 2006;24(2):101-115.
8. Zhang TT, Cui B, Dai DZ, Tang XY. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol. 2005;46(6): 727-734.
9. Zhang TT, Cui B, Dai DZ, Su W. CPU 86017, p-chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway. Acta Pharmacol Sin. 2005;26(11):1309-1316.
10. Na T, Huang ZJ, Dai DZ, Zhang Y, Dai Y. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. Acta Pharmacol Sin. 2007;28(6):773-782.
11. Qi MY, Feng Y, Dai DZ, Li N, Cheng YS, Dai Y. CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity. Acta Pharmacol Sin. 2010;31(2):165-174.
12. Li N, Dai DZ, Dai Y. CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):541-552.
13. Cui B, Cheng YS, Dai DZ, Li N, Zhang TT, Dai Y. CPU0213, a nonselective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol. 2009;36(2):169-175.
14. Yu T, Sheu SS, Robotham JL, Yoon Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc Res. 2008;79(2):341-351.
15. Fatehi-Hassanabad Z, Chan CB, Furman BL. Reactive oxygen species and endothelial function in diabetes. Eur J Pharmacol. 2010;636(1-3):8-17.
16. Xu J, Li N, Dai DZ, Yu F, Dai Y. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase, ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol. 2008;52(1):42-48.
17. Lassegue B, Clempus RE: Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285: R277-R297.
18. Li N, Jia N, Dai DZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKC epsilon. Eur J Pharmacol. 2008; 591(1-3):211-218.
19. Cottone S, Mulè G, Guarneri M, et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant. 2009;24(2):497-503.
20. Bruce-Keller AJ, Gupta S, Parrino TE, et al. NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal. 2010;12(12):1371-1382.
21. Xu M, Dai DZ, Zhang Q, Cheng YS, Dai Y. Upregulated NADPH oxidase contributes to diabetic testicular complication and is relieved by strontium fructose 1,6-diphosphate. Exp Clin Endocrinol Diabetes. 2010;118(7):459-465.
22. Tang XY, Liu Q, Dai DZ, Dai Y. CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium. Pharmacol Rep. 2008; 60(4):524-531.
23. Shen GX. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can J Physiol Pharmacol. 2010; 88(3):241-248.
24. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol. 2006;47(6):729-735.
25. Qi MY, Liu HR, Dai DZ, Li N, Dai Y. Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats. J Pharm Pharmacol. 2008;60(12): 1687-1694.
26. Zhang Q, Liu HR, Ying HJ, Dai DZ, Tang XY, Dai Y. Strontium fructose 1,6-diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin-treated rats. J Pharm Pharmacol. 2009;61(2): 229-236.
27. Matsuo J, Oku H, Kanbara Y, Kobayashi T, Sugiyama T, Ikeda T. Involvement of NADPH oxidase and protein kinase C in endothelin-1-induced superoxide production in retinal microvessels. Exp Eye Res. 2009;89(5):693-699.
28. Zeng Q, Zhou Q, Yao F, O'Rourke ST, Sun C. Endothelin-1 regulates cardiac L-type calcium channels via NAD(P)H oxidase-derived superoxide. J Pharmacol Exp Ther. 2008;326(3):732-738.
29. Duan J, Xu H, Dai S, et al. Phytoestrogen alpha-zearalanol inhibits homocysteine-induced endothelin-1 expression and oxidative stress in human umbilical vein endothelial cells. Atherosclerosis. 2008;197(2): 549-555.
30. Hong EH, Lee SJ, Kim JS, et al. Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. J Biol Chem. 2010;285(2):1283-1295.
31. Deedwania P, Srikanth S. Diabetes and vascular disease. Expert Rev Cardiovasc Ther. 2008;6(1):127-138.
32. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16(1):94-112.
33. Chronic renal disease, Chapter 3, Disease of kidney and Urinary system, In: Tierney LM, McPhee SJ, Papadakis MA, editors. Current Medical Diagnosis and Treatment. McGraw Hill/The People Health Publication, Beijing, China; 2002:283-290.
34. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest. 2006;36:78-88.
35. Drzewoski J, Kasznicki J, Trojanowski Z. The role of "metabolic memory" in the natural history of diabetes mellitus. Pol Arch Med Wewn. 2009;119(7-8):493-500.
36. Matsumoto T, Kobayashi T, Kamata K. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res. 2008;44(2):41-55.
37. Hamed SA, Hamed EA, Ezz Eldin AM, Mahmoud NM. Vascular risk factors, endothelial function, and carotid thickness in patients with migraine: relationship to atherosclerosis. J Stroke Cerebrovasc Dis. 2010;19(2):92-103.
38. Kalogeropoulou K, Mortzos G, Migdalis I, et al. Carotid atherosclerosis in type 2 diabetes mellitus: potential role of endothelin-1, lipoperoxides, and prostacyclin. Angiology. 2002;53(3):279-285.
39. Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther. 2009;27(3):151-158.
40. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens. 2008;30(3):267-276.
41. Yamanari H, Nakamura K, Miura D, Yamanari S, Ohe T. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. Clin Exp Hypertens. 2009;31(7):585-594.
42. Kuklinska AM, Mroczko B, Musial WJ, et al. Diagnostic biomarkers of essential arterial hypertension: the value of prostacyclin, nitric oxide, oxidized-LDL, and peroxide measurements. Int Heart J. 2009;50(3):341-351.
43. Kagota S, Tada Y, Kubota Y, et al. Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. J Cardiovasc Pharmacol. 2007;50(6):677-685.
44. Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension. 2003;42(1):43-48.
45. Luo L, Dai DZ, Dai Y. Effect of the endothelin receptor antagonist CPU0213, and its modulation by rifampin, on cardiac and vascular tissue following chronic isoproterenol treatment. Clin Exp Pharmacol Physiol. 2008;35(7):757-765.
46. Nguyen A, Thorin-Trescases N, Thorin E. Working under pressure: coronary arteries and the endothelin system. Am J Physiol Regul Integr Comp Physiol. 2010 Mar 17. [Epub ahead of print]
47. Galetta F, Franzoni F, Virdis A, et al. Endothelium-dependent vasodilation and carotid artery wall remodeling in athletes and sedentary subjects. Atherosclerosis. 2006;186(1):184-192.
48. Djuric D, Popovic Z, Petrovic J, Bojic M. Age-related progressive brachial artery endothelial dysfunction precedes the changed carotid and left ventricular geometry in healthy humans. Angiology. 1999;50(7):555-561.
49. Bigornia SJ, Mott MM, Hess DT, et al. Long-term successful weight loss improves vascular endothelial function in severely obese individuals. Obesity (Silver Spring). 2010;18(4):754-759.
50. Yang XZ, Liu Y, Mi J, Tang CS, DU JB. Pre-clinical atherosclerosis evaluated by carotid artery intima-media thickness and the risk factors in children. Chin Med J (Engl). 2007;120(5):359-362.
51. Wittekoek ME, de Groot E, Prins MH, Trip MD, Büller HR, Kastelein JJ. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis. 1999;146(2):271-279.
52. Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol. 2008;6(3):195-203.
53. Vladimirova-Kitova LG, Manukov IH, Sirakova I, Deneva TI. Evaluation of the relationship between flow-mediated vasodilation and some atherogenic risk markers in severe hypercholesterolemia. Folia Med (Plovdiv). 2008;50(1):22-28.
54. Xia W, Feng W, Guan M, Yu Y, Li J, Qu X. Increased levels of asymmetric dimethylarginine and C-reactive protein are associated with impaired vascular reactivity in essential hypertension. Clin Exp Hypertens. 2010;32(1):43-48.
55. Rodionov RN, Dayoub H, Lynch CM, et al. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res. 2010;106(3): 551-558.
56. Lind L, Larsson A, Teerlink T. L-Arginine is related to endotheliumdependent vasodilation in resistance and conduit arteries in divergent ways. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis. 2009;203(2): 544-549.
57. Gates PE, Boucher ML, Silver AE, Monahan KD, Seals DR. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. J Appl Physiol. 2007;102(1):63-71.
58. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009;179(1):35-40.
59. Zheng L, Li J, Hu D, et al. Association of low ankle-brachial index with mortality in patients with ischemic heart disease. J Atheroscler Thromb. 2010 Mar 13. [Epub ahead of print]
60. Purroy F, Coll B, Oró M, et al. Predictive value of ankle brachial index in patients with acute ischaemic stroke. Eur J Neurol. 2009 Nov 24. [Epub ahead of print]
61. Topakian R, Nanz S, Rohrbacher B, Koppensteiner R, Aichner FT; For the OECROSS Study Group. High prevalence of peripheral arterial disease in patients with acute ischaemic stroke. Cerebrovasc Dis. 2010;29(3):248-254.
62. Oksala NK, Viljamaa J, Saimanen E, Venermo M; For the ATTAC study group. Modified ankle-brachial index detects more patients at risk in a Finnish primary health care. Eur J Vasc Endovasc Surg. 2010;39(2):227-233.
63. Suominen V, Uurto I, Saarinen J, Venermo M, Salenius J. PAD as a risk factor for mortality among patients with elevated ABI - a clinical study. Eur J Vasc Endovasc Surg. 2010;39(3):316-322.
64. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841-848.
65. Al-Wakeel JS, Hammad D, Al Suwaida A, Mitwalli AH, Memon NA, Sulimani F. Microvascular and macrovascular complications in diabetic nephropathy patients referred to nephrology clinic. Saudi J Kidney Dis Transpl. 2009;20(1):77-85.
66. An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res. 2007;75(4):702-709.
67. De Giusti VC, Correa MV, Villa-Abrille MC, et al. The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci. 2008;83(7-8):264-271.
68. Yamaguchi O, Kaneshiro T, Saitoh S, Ishibashi T, Maruyama Y, Takeishi Y. Regulation of coronary vascular tone via redox modulation in the alpha1-adrenergic-angiotensin-endothelin axis of the myocardium. Am J Physiol Heart Circ Physiol. 2009;296(1):H226-H232.
69. Isaka M, Kudo A, Imamura M, Kawakami H, Yasuda K. Endothelin receptors, localized in sympathetic nerve terminals of the heart, modulate norepinephrine release and reperfusion arrhythmias. Basic Res Cardiol. 2007;102(2):154-162.
70. Peng HJ, Dai DZ, Ji H, Dai Y. The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol. Eur J Pharmacol. 2010;634(1-3):101-106.